July 25, 2025 5:13pm

While indexes trade higher closing out a winning week

Investors are gearing up for a busy week of sector earnings

Earnings: 7/29, Tuesday = uniQure NV (QURE), 7/30, Wednesday = MiMedx (MDXG), 7/31, Thursday = Alnylam Pharmaceuticals (ALNY), Vericel (VCERL), 8/1 = Ionis Pharmaceuticals (IONS) and Moderna (MRNA), 8/5, Tuesday = AxoGen (AXGN)

Never above you. Never below you. Always beside you … I say what others won’t, so you can do what others can’t!

Never leave an investor uninformed! 

TGIF

My perspective is retail investors should roll-the-dice with econ readings until earnings season kicks-in and momentum wains in the cell and gene therapy sector. NO all ins as historically “our” universe slips and slides as the “season’ resumes; so, hang-in with those with solid partners, lengthened runways and solid cash positions leveraged by solid/stable management teams!

 

Friday’s RegMed Investors’ (RMi) pre-open: Weakening breadth after sector cooled … https://www.regmedinvestors.com/articles/14013

Thursday night’s RegMed Investors (RMi) Closing Bell: Econs flash their “six” with expectation and in anticipation … https://www.regmedinvestors.com/articles/14012

RegMed Investors (RMi) Research Note: Sustaining a Loser … https://www.regmedinvestors.com/articles/13812

 

Friday: The Dow closed UP +208.01 points or +0.47%, the S&P closed UP +25.29 points or +0.40% while the Nasdaq closed UP +50.36 points or +0.24%

  • Theme of the session, Friday as it closes out a winning week following solid earnings results and the latest trade developments
  • In the week, the Dow tracked a +1.3%, the Nasdaq +1% and the S&P 500 +1.5% increases

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy

  • Next week is also when the Fed is scheduled to meet widely expected to keep interest rates at their current target range of 4.25% to 4.5%.

Friday’s advance/decline line opened negative with 11 incliners, 19 decliners and 5 flats ending with a positive close of 17 incliners, 14 decliners and 4 flats  

Metrics:  Friday, the IBB was up +0.07%, the XBI was up +0.12% while the VIX was down -0.46 points or -2.99% at 14.93

 

Q3 – 7/25 – 1 market holiday, 14 positive and 5 negative closes

Q2/25:

  • June – 1 market holiday, 1 neutral, 9 negative and 11 positive closes
  • May – 1 market holiday, 10 negative and 11 positive closes
  • April – 11 positive and 10 negative closes

 

Friday Closing UP (10 of 17) 

  • Intellia Therapeutics (NTLA +$0.82 after Thursday’s -$1.46, Wednesday’s +$0.75, Tuesday’s +$0.86 and Monday’s +$0.57),
  • Alnylam Pharmaceuticals ALNY +$0.81 after Thursday’s+$2.36),
  • Beam Therapeutics (BEAM +$0.77 after Thursday’s -$1.21, Wednesday’s +$0.62, Tuesday’s +$0.51 and Monday’s +$0.28),
  • Cellectis SA (CLLS +$0.52 after Thursday’s -$0.33),
  • Generation Bio (GBIO +$0.41),
  • Vericel (VCEL +$0.40 after Thursday’s -$0.63, Wednesday’s +$2.37, Tuesday’s +$2.52 after Monday’s +$0.12),
  • Solid Biosciences (SLDB +$0.32),
  • BioLife Solutions (BLFS +$0.32),
  • AxoGen (AXGN +$0.16 after Thursday’s -$0.25, Wednesday’s +$0.92, Tuesday’s +$0.93 and Monday’s +$0.33),
  • Moderna (MRNA +$0.14 after Thursday’s -$0.66, Wednesday’s +$1.94, Tuesday’s +$1.76 and Monday’s -$0.29)

Flat (4)

  • bluebird bio (BLUE) P/E acquired
  • Blueprint Medicine (BPMC) acquired by SNY
  • Homology Medicine (FIXX)
  • Verve Therapeutics (VERV) – acquired by LLY

Friday’s Closing DOWN (10 of 14): 

  • Lenz Therapeutics (LENZ -$1.78 after Thursday’s -$0.35),
  • CRISPR Therapeutics (CRSP -$1.30 after Thursday’s -$2.08, Wednesday’s +$2.21, Tuesday’s +$0.60 and Monday’s +$0.20),
  • Mesoblast (MESO -$0.62 after Thursday’s +$0.89 after Wednesday’s +$1.01 after Tuesday’s +$0.43 after Monday’s -$0.97),
  • Regenxbio (RGNX -$0.17 after Thursday’s +$0.04),
  • Prime Medicine (PRME -$0.14 after Thursday’s -$0.29),
  • Editas Medicine (EDIT -$0.11),
  • uniQure NV (QURE -$0.10),
  • Caribou Biosciences (CRBU -$0.09),
  • MiMedx (MDXG -$0.08),
  • Agenus (AGEN -$0.08),

 

The BOTTOM LINE: the week finishes with new highs on growing confidence that the U.S. will strike favorable trade deals with major trading partners and that tariffs won't choke growth, and optimism around the earnings. Some indicators …

  • While the Russell 2000 rose 0.4% on Friday, notching a 0.9% weekly increase.
  • Volume on the Nasdaq was lower compared with Thursday. Breadth was positive on the Nasdaq by a small margin.
  • The yield on the benchmark 10-year Treasury note fell to 4.39%.

The cell and gene therapy sector closed negative on Thursday following Wednesday (7/23), Tuesday and Monday’s positive closes …

  • After slipping last Friday (7/18) following a positive close on last Thursday and Wednesday having slid on Tuesday after Monday’s positive close
  • And popping on the previous Friday, Thursday and Wednesday continued the upside after Tuesday positive close and diving on Monday ….
  • After the previous, previous week’s pop on multiple positive closes (Thursday, Wednesday, Tuesday and Monday) in this new month, July and Q.

 

Earnings are a’comin: 7/29, Tuesday = uniQure NV (QURE), 7/30, Wednesday = MiMedx (MDXG), 7/31, Thursday = Alnylam Pharmaceuticals (ALNY), Vericel (VCERL), 8/1 = Ionis Pharmaceuticals (IONS) and Moderna (MRNA), 8/5, Tuesday = AxoGen (AXGN)

 

As I also wrote, the “June Swoon” is over … however, July is much better than past months. Although, I consider the so-called summer rally … peripatetic or wandering.”

  • There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

July evolves: understand the “flow” …

  • 7/25 – Friday closed positive with 17 positive, 14 negative and 4 flats
  • 7/24 – Thursday closed negative with 7 positive, 25 negative and 3 flats
  • 7/23 – Wednesday closed positive with 30 positive, 1 negative and 4 flats
  • 7/22 – Tuesday closed positive with 19 positive, 10 negative and 6 flats
  • 7/21 – Monday closed positive with 17 positive, 14 negative and 4 flats

Last week:

  • 7/18 – Friday closed negative with 10 positive, 21 negative and 4 flats
  • 7/17 – Thursday closed positive with 17 positive, 14 negative and 4 flats
  • 7/16 - Wednesday closed positive with 24 positive, 5 negative and 6 flats
  • 7/15 – Tuesday closed negative with 3 positive, 29 negative and 3 flats
  • 7/14 - Monday closed positive with 20 positive, 11 negative and 4 flats

The previous week:

  • 7/11 - Friday closed negative with 5 positive, 28 negative and 2 flats
  • 7/10 - Thursday closed positive with 19 positive, 14 negative and 2 flats
  • 7/9 – Wednesday closed positive with 28 positive, 5 negative and 2 flats
  • 7/8 - Tuesday closed positive with 22 positive, 10 negative and 3 flats
  • 7/7 – Monday closed negative with 6 positive, 27 negative and 2 flats

 

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.
  • I was once told by a “very” prominent figure early in my career, “write it right, keep it tight without hype and never lose the stride to guide the reader” – they were pretty simple instructions to follow!

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Friday: Intellia Therapeutics (NTLA), Alnylam Pharmaceuticals (ALNY) and Beam Therapeutics (BEAM)
  • Thursday: Alnylam Pharmaceuticals (ALNY), Mesoblast (MESO) and Lenz Pharmaceuticals (LENZ)
  • Wednesday: Vericel (VCEL), CRISPR Therapeutics (CRSP) and Moderna (MRNA)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), Vericel (VCEL) and Moderna (MRNA)
  • Monday: CRISPR Therapeutics (CRSP), Alnylam Pharmaceuticals (ALNY) and Intellia Therapeutics (NTLA)

The worst three (3) in the session: 

  • Friday: Lenz Pharmaceuticals (LENZ), CRISPR Therapeutics (CRSP) and Mesoblast (MESO)
  • Thursday: CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA) and Beam Therapeutics (BEAM)
  • Wednesday: Agenus AGEN)
  • Tuesday: Lenz Pharmaceuticals (LENZ), Precigen (PGEN) and uniQure NV (QURE)
  • Monday: Mesoblast (MESO), Vericel (VCEL) and uniQure NV (QURE)

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.